Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders

A pharmaceutical composition comprising a compound of Formula I

• wherein
• Y is CH or N;
• Ar1 is phenyl or pyridyl each optionally substituted with 1 or 2 substituents each selected independently from (C1-C3)alkoxy, halo, OH, CF3, CN, NO2and (C1-C3)alkyl, said alkyl being optionally substituted with CF3;
• Ar2 is phenyl or pyridyl each optionally substituted with 1 or 2 substituents each independently selected from halo, OH, CN, NO2, CF3, (C1-C6)alkoxy, NR1R1, S(O)2R2, C(O)R3, and (C1-C6)alkyl optionally substituted with R4;
• R1 is selected from H, S(O)2N[(C1-C3)alkyl]2, S(O)2NH(C1-C3)alkyl, C(O)(C1-C3)alkyl where said alkyl is optionally substituted with NR5R5, and (C1-C3)alkyl where said alkyl is optionally substituted with 1 or 2 substituents each selected independently from OH and (C1-C3)alkoxy,
• with the proviso that in any NR1R1 group when one R1 is S(O)2N[(C1-C3)alkyl]2, S(O)2NH(C1-C3)alkyl or C(O)(C1-C3)alkyl then the other R1 must be other than S(O)2N[(C1-C3)alkyl]2, S(O)2NH(C1-C3)alkyl or C(O)(C1-C3)alkyl;
• R2 is selected from (C1-C3)alkyl, pyrrolidinyl, and NH(C1-C3)alkyl where said alkyl is optionally substituted with OH;
• R3 is selected from (C1-C3)alkyl, (C1-C3)alkoxy, morpholinyl, pyrrolidinyl, piperidinyl, and NH(C1-C3)alkyl where said alkyl is optionally substituted with OH, (C1-C3)alkoxy or N[(C1-C3)alkyl]2;
• R4 is selected from OH, CN, CF3, (C1-C3)alkoxy, C(O)NR5R5, NR5R5, and piperidinyl;
• and
• R5 is selected from H, (C1-C3)alkyl, C(O)(C1-C3)alkyl, S(O)2(C1-C3)alkyl and piperidinyl, with the proviso that in any NR5R5 group when one R5 is C(O)(C1-C3)alkyl or S(O)2(C1-C3)alkyl, then the other R5 must be other than C(O)(C1-C3)alkyl or S(O)2(C1-C3)alkyl;
• and
• excluding (3-amino-6-phenylfuro[2,3-b]pyridin-2-yl)(phenyl)methanone, (3-amino-6-phenylfuro[2,3-b]pyridin-2-yl)(4-nitrophenyl)methanone, and (3-amino-6-(4-methylphenyl)furo[2,3-b]pyridin-2-yl)(phenyl)methanone,
• or a pharmaceutically acceptable salt thereof,
• and a pharmaceutically acceptable carrier.

A method of treating a hyper-proliferative disorder comprising the administration to a patient in need thereof of an effective amount of a compound of Formula

• wherein
• Y is CH or N;
• Ar1 is phenyl or pyridyl each optionally substituted with 1 or 2 substituents each selected independently from (C1-C3)alkoxy, halo, OH, CF3, CN, NO2 and (C1-C3)alkyl, said alkyl being optionally substituted with CF3;
• Ar2 is phenyl or pyridyl each optionally substituted with 1 or 2 substituents each independently selected from halo, OH, CN, NO2, CF3, (C1-C6)alkoxy, NR1R1, S(O)2R2, C(O)R3, and (C1-C6)alkyl optionally substituted with R4;
• R1 is selected from H, S(O)2N[(C1-C3)alkyl]2, S(O)2NH(C1-C3)alkyl, C(O)(C1-C3)alkyl where said alkyl is optionally substituted with NR5R5, and (C1-C3)alkyl where said alkyl is optionally substituted with 1 or 2 substituents each selected independently from OH and (C1-C3)alkoxy,
• with the proviso that in any NR1R1 group when one R1 is S(O)2N[(C1-C3)alkyl]2, S(O)2NH(C1-C3)alkyl or C(O)(C1-C3)alkyl then the other R1 must be other than S(O)2N[(C1-C3)alkyl]2, S(O)2NH(C1-C3)alkyl or C(O)(C1-C3)alkyl;
• R2 is selected from (C1-C3)alkyl, pyrrolidinyl, and NH(C1-C3)alkyl where said alkyl is optionally substituted with OH;
• R3 is selected from (C1-C3)alkyl, (C1-C3)alkoxy, morpholinyl, pyrrolidinyl, piperidinyl, and NH(C1-C3)alkyl where said alkyl is optionally substituted with OH, (C1-C3)alkoxy or N[(C1-C3)alkyl]2;
• R4 is selected from OH, CN, CF3, (C1-C3)alkoxy, C(O)NR5R5, NR5R5, and piperidinyl;
• and
• R5 is selected from H, (C1-C3)alkyl, C(O)(C1-C3)alkyl, S(O)2(C1-C3)alkyl and piperidinyl, with the proviso that in any NR5R5 group when one R5 is C(O)(C1-C3)alkyl or S(O)2(C1-C3)alkyl, then the other R5 must be other than C(O)(C1-C3)alkyl or S(O)2(C1-C3)alkyl;
• and
• excluding (3-amino-6-phenylfuro[2,3-b]pyridin-2-yl)(phenyl)methanone, (3-amino-6-phenylfuro[2,3b]pyridin-2-yl)(4-nitrophenyl)methanone, and (3-amino-6-(4-methylphenyl)furo[2,3-b]pyridin-2-yl)(phenyl)methanone,
• or a pharmaceutically acceptable salt thereof.